Published in Oncotarget on May 30, 2015
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models. BMC Cancer (2015) 1.44
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol (2016) 0.82
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Lett (2016) 0.78
Structural Basis of Targeting the Exportin CRM1 in Cancer. Cells (2015) 0.77
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol (2016) 0.77
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med (2016) 0.76
Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Mol Cancer Ther (2017) 0.75
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol (2017) 0.75
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res (2017) 0.75
Surfing the p53 network. Nature (2000) 35.36
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Advances in malignant mesothelioma. N Engl J Med (2005) 8.50
Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A (1999) 6.81
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood (2012) 2.65
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05
Phase I trial of elactocin. Br J Cancer (1996) 2.01
The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer (2009) 1.97
Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res (2007) 1.87
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia (2012) 1.77
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia (2013) 1.76
Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery (2009) 1.68
Prognostic value of CRM1 in pancreas cancer. Clin Invest Med (2009) 1.65
The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep (2009) 1.64
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol (2012) 1.47
Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology (2012) 1.44
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Targeting survivin in cancer. Cancer Lett (2012) 1.44
Protein localization in disease and therapy. J Cell Sci (2011) 1.42
Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A (2013) 1.21
Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev (2011) 1.14
The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol (2012) 1.14
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13
XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther (2014) 1.13
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol (2014) 1.11
Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget (2014) 1.05
Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis (2010) 1.03
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci (2014) 1.02
Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol (2007) 0.98
In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res (1988) 0.97
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol (2008) 0.96
SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents. J Hematol Oncol (2014) 0.94
KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer (2014) 0.94
Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One (2014) 0.93
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia (2014) 0.93
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol (2014) 0.91
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer (2013) 0.88
The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2013) 0.83
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. Int J Cancer (2014) 0.80
Strategies to Strike Survival Networks in Cancer. Crit Rev Oncog (2016) 0.75